305 related articles for article (PubMed ID: 27417323)
21. Ranolazine for the treatment of chronic stable angina: a cost-effectiveness analysis from the UK perspective.
Coleman CI; Freemantle N; Kohn CG
BMJ Open; 2015 Nov; 5(11):e008861. PubMed ID: 26546142
[TBL] [Abstract][Full Text] [Related]
22. Extended-release ranolazine: critical evaluation of its use in stable angina.
Truffa AA; Newby LK; Melloni C
Vasc Health Risk Manag; 2011; 7():535-9. PubMed ID: 21915171
[TBL] [Abstract][Full Text] [Related]
23. Ranolazine: a review of its use in chronic stable angina pectoris.
Siddiqui MA; Keam SJ
Drugs; 2006; 66(5):693-710. PubMed ID: 16620147
[TBL] [Abstract][Full Text] [Related]
24. Ivabradine in combination with beta-blocker reduces symptoms and improves quality of life in elderly patients with stable angina pectoris: age-related results from the ADDITIONS study.
Müller-Werdan U; Stöckl G; Ebelt H; Nuding S; Höpfner F; Werdan K;
Exp Gerontol; 2014 Nov; 59():34-41. PubMed ID: 25193811
[TBL] [Abstract][Full Text] [Related]
25. Pharmacologic management of chronic stable angina.
Dixit D; Kimborowicz K
JAAPA; 2015 Jun; 28(6):. PubMed ID: 25989429
[TBL] [Abstract][Full Text] [Related]
26. The use of ranolazine in non-anginal cardiovascular disorders: A review of current data and ongoing randomized clinical trials.
Mihos CG; Krishna RK; Kherada N; Larrauri-Reyes M; Tolentino A; Santana O
Pharmacol Res; 2016 Jan; 103():49-55. PubMed ID: 26546970
[TBL] [Abstract][Full Text] [Related]
27. Impact of ranolazine on coronary microvascular dysfunction (MICRO) study.
Ahmed B; Mondragon J; Sheldon M; Clegg S
Cardiovasc Revasc Med; 2017 Sep; 18(6):431-435. PubMed ID: 28576663
[TBL] [Abstract][Full Text] [Related]
28. Ivabradine in combination with Beta-blockers in patients with chronic stable angina after percutaneous coronary intervention.
Werdan K; Ebelt H; Nuding S; Höpfner F; Stöckl G; Müller-Werdan U
Adv Ther; 2015 Feb; 32(2):120-37. PubMed ID: 25687888
[TBL] [Abstract][Full Text] [Related]
29. The usefulness of ranolazine for the treatment of refractory chronic stable angina pectoris as determined from a systematic review of randomized controlled trials.
Banon D; Filion KB; Budlovsky T; Franck C; Eisenberg MJ
Am J Cardiol; 2014 Mar; 113(6):1075-82. PubMed ID: 24462341
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina).
Kosiborod M; Arnold SV; Spertus JA; McGuire DK; Li Y; Yue P; Ben-Yehuda O; Katz A; Jones PG; Olmsted A; Belardinelli L; Chaitman BR
J Am Coll Cardiol; 2013 May; 61(20):2038-45. PubMed ID: 23500237
[TBL] [Abstract][Full Text] [Related]
31. Update on the medical treatment of stable angina.
Gayet JL; Paganelli F; Cohen-Solal A
Arch Cardiovasc Dis; 2011 Oct; 104(10):536-44. PubMed ID: 22044707
[TBL] [Abstract][Full Text] [Related]
32. Effects of Exercise Training With and Without Ranolazine on Peak Oxygen Consumption, Daily Physical Activity, and Quality of Life in Patients With Chronic Stable Angina Pectoris.
Willis LH; Slentz CA; Johnson JL; Kelly LS; Craig KP; Hoselton AL; Kraus WE
Am J Cardiol; 2019 Sep; 124(5):655-660. PubMed ID: 31296368
[TBL] [Abstract][Full Text] [Related]
33. Ranolazine in patients with type 2 diabetes and chronic angina: A cost-effectiveness analysis and assessment of health-related quality-of-life.
Nguyen E; Coleman CI; Kohn CG; Weeda ER
Int J Cardiol; 2018 Dec; 273():34-38. PubMed ID: 30266352
[TBL] [Abstract][Full Text] [Related]
34. Ranolazine for the treatment of refractory angina in a veterans population.
Greene RS; Rangel RM; Edwards KL; Chastain LM; Brouse SD; Alvarez CA; Collins LJ; Brilakis ES; Banerjee S
Cardiovasc Revasc Med; 2012; 13(2):141.e1-5. PubMed ID: 21856249
[TBL] [Abstract][Full Text] [Related]
35. Role of metabolically active drugs in the management of ischemic heart disease.
Schofield RS; Hill JA
Am J Cardiovasc Drugs; 2001; 1(1):23-35. PubMed ID: 14728049
[TBL] [Abstract][Full Text] [Related]
36. Long-Term Preservation of Left Ventricular Systolic Function in Patients With Refractory Angina Pectoris and Inducible Myocardial Ischemia on Optimal Medical Therapy.
Slavich M; Maranta F; Fumero A; Godino C; Giannini F; Oppizzi M; Colombo A; Fragasso G; Margonato A
Am J Cardiol; 2016 May; 117(10):1558-1561. PubMed ID: 27055755
[TBL] [Abstract][Full Text] [Related]
37. Pharmacological approaches of refractory angina.
Giannopoulos AA; Giannoglou GD; Chatzizisis YS
Pharmacol Ther; 2016 Jul; 163():118-31. PubMed ID: 27013345
[TBL] [Abstract][Full Text] [Related]
38. Glucose-Lowering Medications and Angina Burden in Patients with Stable Coronary Disease: results from the Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina (TERISA) Trial.
Arnold SV; McGuire DK; Spertus JA; Tang F; Yue P; Inzucchi SE; Belardinelli L; Chaitman BR; Kosiborod M
Am Heart J; 2015 Oct; 170(4):753-759.e2. PubMed ID: 26386799
[TBL] [Abstract][Full Text] [Related]
39. Ranolazine: a review of its use in chronic stable angina pectoris.
Keating GM
Drugs; 2008; 68(17):2483-503. PubMed ID: 19016575
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of ranolazine in patients with chronic stable angina.
Kloner RA; Hines ME; Geunes-Boyer S
Postgrad Med; 2013 Nov; 125(6):43-52. PubMed ID: 24200760
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
